Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Brigatinib (Alunbrig) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
• The information provided is derived from 15 systematic reviews and meta-analyses studies.
• Lorlatinib showed better progression-free survival (PFS), especially in patients with baseline brain metastasis, but had a poorer safety profile compared to Brigatinib.
• Alectinib demonstrated the highest overall survival rates and was safer than Brigatinib, particularly in global and Asian patient populations.
• Ensartinib exhibited superior efficacy over Brigatinib specifically within Asian populations regarding PFS outcomes.
• In second-line treatments post-crizotinib, Alectinib outperformed Brigatinib in terms of PFS while also having a better safety profile; however, both drugs were less safe when compared to other ALK inhibitors like Ceritinib.
• Common adverse events associated with Brigatinib include gastrointestinal reactions, hypertension, coughs, headaches, elevated liver enzymes, and higher incidence rates for Grade 3–4 adverse effects relative to many other such inhibitors.
• Despite its effectiveness in improving quality of life measures among users and intracranial activity in first-line settings, Alunbrig did not surpass alternatives in broader population contexts.